Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease - Test2 - elhamkhani - TriplyDB

Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease

Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease

http://www.wikidata.org/entity/Q28740551

about

Molecular determinants of α-synuclein mutants' oligomerization and membrane interactions Mechanism of Anti-α-Synuclein Immunotherapy Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation Disease-modifying therapeutic directions for Lewy-Body dementias Insights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based Therapies Multiple system atrophy: a clinical and neuropathological perspective Adult hippocampal neurogenesis in Parkinson's disease: impact on neuronal survival and plasticity Proteolytic clearance of extracellular α-synuclein as a new therapeutic approach against Parkinson disease Vaccination strategies for Parkinson disease: induction of a swift attack or raising tolerance?Neuroimmunological processes in Parkinson's disease and their relation to α-synuclein: microglia as the referee between neuronal processes and peripheral immunity Characterization of cognitive deficits in rats overexpressing human alpha-synuclein in the ventral tegmental area and medial septum using recombinant adeno-associated viral vectors Alpha-Synuclein Oligomers-Neurotoxic Molecules in Parkinson's Disease and Other Lewy Body Disorders Friend or foe: the dichotomous impact of T cells on neuro-de/re-generation during aging Antibodies against alpha-synuclein reduce oligomerization in living cells Glucocerebrosidase modulates cognitive and motor activities in murine models of Parkinson's disease.Time course and progression of wild type α-synuclein accumulation in a transgenic mouse model.Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.ESCRT-mediated uptake and degradation of brain-targeted α-synuclein single chain antibody attenuates neuronal degeneration in vivo.Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy.The Cleavage Effect of Mesenchymal Stem Cell and Its Derived Matrix Metalloproteinase-2 on Extracellular α-Synuclein Aggregates in Parkinsonian Models Combined immunotherapy with "anti-insulin resistance" therapy as a novel therapeutic strategy against neurodegenerative diseases.Autoimmune antibody decline in Parkinson's disease and Multiple System Atrophy; a step towards immunotherapeutic strategies.Towards translational therapies for multiple system atrophy Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice.Nanomolar concentration of alpha-synuclein enhances dopaminergic neuronal survival via Akt pathway.Life extension factor klotho enhances cognition.Cognitive dysfunction and depression in Parkinson's disease: what can be learned from rodent models?Phospholipase D1 regulates autophagic flux and clearance of α-synuclein aggregates Life extension factor klotho prevents mortality and enhances cognition in hAPP transgenic mice.Lewy body dementias.α-Synuclein and anti-α-synuclein antibodies in Parkinson's disease, atypical Parkinson syndromes, REM sleep behavior disorder, and healthy controls Novel therapeutic approaches in multiple system atrophy Anti-human α-synuclein N-terminal peptide antibody protects against dopaminergic cell death and ameliorates behavioral deficits in an AAV-α-synuclein rat model of Parkinson's disease.A generic method for design of oligomer-specific antibodies.Cognition in movement disorders: where can we hope to be in ten years?A novel triple repeat mutant tau transgenic model that mimics aspects of pick's disease and fronto-temporal tauopathies.Chaperoned amyloid proteins for immune manipulation: α-Synuclein/Hsp70 shifts immunity toward a modulatory phenotype Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration.Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy

P2860

Q24312185-B3B475AF-8049-4421-B386-C744863EC254 Q26772943-DD94CAA5-5091-4669-A529-09D763F821C0 Q26781130-10B6A1CD-40FA-4D78-A3D7-9027FC1DE497 Q26782907-5A570E8F-1B5B-4B7E-BDAA-2B0AA0AF4ABA Q26795984-AB54343D-5EAD-43B2-B21D-A5AF94F77A60 Q26829838-A0EEA8E8-5630-435A-A900-6253203A5A08 Q26862840-BE750F4E-AA8F-448E-BC77-BC241A8DE0E9 Q27005843-ED16A351-5F19-4B59-B2F1-04597F5D75E6 Q27015811-B12BD60C-93F4-4899-BE5C-C0FF2F074E71 Q27027973-D5A734E5-98E3-40B4-B993-3EBB8533E8B5 Q27318127-B7204394-79DC-484D-8E3B-6CD3E346663C Q28067429-0F873AD9-59FB-4B4B-B1C9-1BFE1F787914 Q28077869-84EC765D-CAB9-4C58-8B54-F82B42B8CA67 Q28743313-4909E027-3516-44C3-ABBF-15F41131BD9D Q30367337-7B59723A-C91F-4E39-80E7-DE4E39445E3D Q30532478-3B928F37-1F15-4A32-B7F1-0111328DF755 Q30578913-F90924C7-9A61-47B9-AC33-05A720727674 Q30650119-623CA080-161B-4CFA-849D-E93A736CEBD5 Q30805841-497D14FD-2622-4A66-9644-9DC53C867322 Q33722313-41C7858B-822E-45E4-AAED-2C6E5FAD5EEF Q33731321-F59D66B8-13D6-4AC2-A989-D93DC0ACEEA1 Q33776552-1FE6BC20-B6FC-47B5-8ADA-F3B804111609 Q33797532-3BCBFF88-6560-4352-8776-3F803D1F2E41 Q33865366-30B24A35-F494-4A36-97C5-1D56C9B237C7 Q33947949-E4F45406-843F-418D-A574-6279AACC893A Q34094699-41AD15D4-0D92-4872-9E15-0CBB269D54B5 Q34252649-81C8CD7A-B4E5-49B9-B1DA-441A30F9945B Q34307633-027B792F-6774-4CB1-91AA-3626A6C0F405 Q34393784-0316CD3B-4BD0-4773-A279-4BB0853AB8C7 Q34462326-B6688790-0DE8-48EE-BB3F-0FA7FE4F0415 Q34502646-23A717F7-8F52-4195-BED4-B0F1B7A7B609 Q34533573-5F43F79E-4EF6-48D2-91AB-0CA6F9CEDBDA Q34696470-75BA9F0A-72DF-40A7-8F02-7C141063190A Q35058359-F33F51BB-391E-4851-9EAF-F565796834CA Q35117526-2A7E4622-7AD4-4E84-BC14-6C95F4E00B72 Q35211553-31F25A1B-2E75-4733-8680-D3E597C582B2 Q35213879-8ED7CA7C-9B63-419D-8A8F-B0AD76781633 Q35285839-E17EE3D3-801C-49D0-9374-7FB133A47FD9 Q35542169-582587A1-966C-49E2-BAC8-B6D5ADB64C8E Q35544737-B6386F69-88AE-43D3-8FE9-804CFDB3164D

P2860

Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease

http://www.wikidata.org/entity/Q28740551

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Passive immunization reduces b ...... nic model of Lewy body disease

@ast

Passive immunization reduces b ...... nic model of Lewy body disease

@en

Passive immunization reduces b ...... nic model of Lewy body disease

@nl

type

label

Passive immunization reduces b ...... nic model of Lewy body disease

@ast

Passive immunization reduces b ...... nic model of Lewy body disease

@en

Passive immunization reduces b ...... nic model of Lewy body disease

@nl

prefLabel

Passive immunization reduces b ...... nic model of Lewy body disease

@ast

Passive immunization reduces b ...... nic model of Lewy body disease

@en

Passive immunization reduces b ...... nic model of Lewy body disease

@nl

P1433

Q28740551-3B49F27E-B92C-4E96-9B1E-265C9F3A0BD1

P1476

Q28740551-02730EDA-0EF8-4FDB-84B2-C8FB19C32F54

P2093

Q28740551-16371214-64DA-4036-AA80-69BBA52F5B54

Q28740551-1B741633-33C3-4D00-9E1A-E544C26F7561

Q28740551-1E787985-FBD2-4B33-93A4-502B875B5CB1

Q28740551-31F8B2D7-DE8F-40D7-BDD9-CA8900E8F321

Q28740551-3EF02DC2-0AB2-417F-89D4-79028AF577A6

Q28740551-40C3A712-84F7-4F93-A5D3-620D182BDC04

Q28740551-5889BFFE-07E8-45E5-8CC8-8D08D3AB0E65

Q28740551-6287EB7E-48C8-47B5-AC6F-F52F67897DCA

Q28740551-D45BF6C4-4F54-4CE3-8ED4-6C008BC5124D

Q28740551-D809C104-4CAF-40DE-AE6A-6A0B3BC1D2A9

P2860

Q28740551-01120840-FFC5-4E56-AEC4-85C7D6A79A37

Q28740551-0305908A-98BC-428C-A197-1F2FFC61F440

Q28740551-03CF5105-5252-4637-8BD1-B0AE89FEF3A7

Q28740551-06F3AEDB-D53A-4E47-B8BD-30110B79E616

Q28740551-0A42CEBE-EBBD-4B69-932A-B7A0E23AC156

Q28740551-135E4B5C-8DE1-42AC-B339-A957E934A5B7

Q28740551-17408866-0907-4272-BB67-7067905850ED

Q28740551-24BB507E-4952-49D3-85BF-AA117F565DF3

Q28740551-2582C752-FB42-45F0-AB95-3319D00CFE01

Q28740551-2A0F9587-9D98-44C7-B8E9-1E5D87EA8A70

P304

Q28740551-F49A39E7-AEC3-4FE6-8ECA-707BC4A28312

P31

Q28740551-61CCD798-978B-4EA5-A34B-C077BAA46E83

P3181

Q28740551-5D7EDE65-FBD2-4550-96F4-A5CF4FAFA631

P356

Q28740551-238D062F-A5C7-426F-9BE9-D0C51B9FCBC2

P407

Q28740551-170029A6-37CD-4474-860A-CEDB2E3FDFBE

P433

Q28740551-8C8AAB30-37CA-44B7-8057-79C428E25392

P478

Q28740551-C77235AF-A8F6-455B-976E-0B3FC7128579

P50

Q28740551-4EA8AB7F-DE21-4E7F-84BC-B0EA76E56951

Q28740551-7C7A9C0E-AF08-49ED-92C4-5A2FD4851535

Q28740551-7F4A552A-A533-40E1-AC6B-B28801917A21

Q28740551-A257EFC8-0B0C-4981-A3EA-A44F936071F3

P577

Q28740551-A4E700B0-6FEC-473A-832A-2357A85D97DA

P5875

Q28740551-CDE0C18D-DEDB-4A5A-AE3E-02A915D4F5B2

P698

Q28740551-6A7550D5-E62A-40A0-B7F1-97F3E4756191

P921

Q28740551-1E6FE5B6-AC8E-4CA9-BF20-3C483668943D

Q28740551-EBE1650C-ECFC-4231-8B90-FF6F24C81B16

P932

Q28740551-192D8C7B-0B1E-4277-8FFE-4832D3B0B739

P3181

P356

JOURNAL.PONE.0019338

P1433

P1476

Passive immunization reduces b ...... nic model of Lewy body disease

@en

P2093

Anthony Adame

http://www.w3.org/2001/XMLSchema#string

Brian Spencer

http://www.w3.org/2001/XMLSchema#string

Christina Patrick

http://www.w3.org/2001/XMLSchema#string

Dale Schenk

http://www.w3.org/2001/XMLSchema#string

Dora Games

http://www.w3.org/2001/XMLSchema#string

Lisa McConlogue

http://www.w3.org/2001/XMLSchema#string

Manuel Buttini

http://www.w3.org/2001/XMLSchema#string

Margarita Trejo

http://www.w3.org/2001/XMLSchema#string

Michael Mante

http://www.w3.org/2001/XMLSchema#string

Peter Seubert

http://www.w3.org/2001/XMLSchema#string

P2860

Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease

Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein

The Parkinson's complex: parkinsonism is just the tip of the iceberg

Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons

The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice.

Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy

Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders

Reduced neuritic outgrowth and cell adhesion in neuronal cells transfected with human alpha-synuclein.

Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments.

Clearance and prevention of prion infection in cell culture by anti-PrP antibodies.

P304

e19338

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1402516

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PONE.0019338

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Eliezer Masliah

Edward Rockenstein

P577

2011-04-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51114485

http://www.w3.org/2001/XMLSchema#string

P698

21559417

http://www.w3.org/2001/XMLSchema#string

P921

P932

3084838

http://www.w3.org/2001/XMLSchema#string